local_hospital

San Camillo Forlanini Hospital

Address
lock Available on a paid plan

Gastroenterology and Digestive Diseases

At San Camillo Forlanini Hospital, research in digestive system diseases focuses on common and complex inflammatory conditions, especially Crohn’s disease and ulcerative colitis. The trials are designed to assess new treatment options, improve long-term disease control, and better understand how to maintain remission in patients with chronic bowel inflammation.

  • Studies in Crohn’s disease and ulcerative colitis
  • Evaluation of therapies aimed at reducing symptoms and supporting remission
  • Research into safer and more durable maintenance strategies

This area reflects the site’s strong clinical activity in gastroenterology and endoscopy, with a clear emphasis on improving everyday care for patients living with inflammatory bowel disease.

Oncology and Hematologic Malignancies

The hospital has a broad portfolio in neoplasms and hemic and lymphatic diseases, with trials spanning non-small cell lung cancer, colorectal cancer, cholangiocarcinoma, bladder cancer, and blood cancers such as diffuse large B-cell lymphoma and acute leukemias. These studies mainly test new cancer therapies, compare treatment combinations, and look for better ways to improve survival and disease control.

  • Non-small cell lung cancer and other advanced solid tumors
  • Colorectal, biliary, and urothelial cancers
  • Lymphoma, multiple myeloma, and acute leukemia

Research at this site also includes biomarker-guided oncology, helping match treatment approaches to tumor features and supporting more personalized cancer care.

Cardiovascular and Cerebrovascular Research

Trials in cardiovascular diseases and nervous system diseases address major conditions such as stroke, atrial fibrillation, heart failure, myocardial infarction, and hypertension. The main goal is to evaluate therapies that may reduce serious events, improve recovery, and lower the risk of future complications.

  • Acute ischemic stroke and high-risk transient ischemic attack
  • Atrial fibrillation and prevention of clot-related events
  • Heart failure and post-infarction cardiovascular risk

These studies combine treatment evaluation with prevention-focused research, supporting better outcomes for patients with high-risk cardiovascular disease.

Autoimmune, Rheumatologic, and Renal Disorders

Another major research focus is immune system diseases, including systemic lupus erythematosus, lupus nephritis, and immunoglobulin A nephropathy. The trials aim to test new immune-targeted therapies, reduce inflammation, and improve protection of kidney function in chronic autoimmune disease.

  • Systemic lupus erythematosus and related disease activity
  • Lupus nephritis and IgA nephropathy
  • Evaluation of therapies that may improve long-term control and organ protection

This area shows a strong interest in refining treatment for complex immune-mediated conditions where sustained control is essential.

Neurology and Neuroimmunology

The site also contributes to research in nervous system diseases, especially multiple sclerosis and radiologically isolated syndrome. These studies are intended to assess new therapies, monitor long-term safety, and support earlier and more effective management of chronic neurological disease.

  • Relapsing-remitting multiple sclerosis and progressive forms of disease
  • Radiologically isolated syndrome
  • Testing treatments designed to slow disease activity and improve stability over time

At San Camillo Forlanini Hospital, this research reflects a wider commitment to immune-related neurological care alongside other chronic specialty areas.

Respiratory and Thoracic Oncology

Within respiratory tract diseases, the site is active in studies of lung cancer, particularly advanced non-small cell lung cancer and small-cell lung cancer. The trials are focused on testing targeted and immune-based treatments, comparing options for first-line and later-line care, and improving outcomes in advanced disease.

  • Advanced non-small cell lung cancer
  • Small-cell lung cancer and rare lung tumor types
  • Research into more effective and better-tolerated cancer therapies

This is one of the most active therapeutic areas at the hospital, linking oncology expertise with precision medicine approaches.

Other Specialized Clinical Research

The trial portfolio also includes studies in musculoskeletal diseases, skin and connective tissue diseases, congenital and neonatal conditions, and broader diagnostic and therapeutic techniques. These projects range from Dupuytren contracture and intestinal malabsorption to research in preterm infants and other supportive care settings, with a focus on improving treatment effectiveness and clinical management.

  • Dupuytren contracture and other musculoskeletal conditions
  • Intestinal malabsorption and neonatal care research
  • Studies aimed at improving diagnostics, symptom control, and supportive treatment

These trials add breadth to the site’s portfolio and show interest in both highly specialized and cross-cutting areas of clinical care.

Site Overview

assignment
103
connected trials
corporate_fare
57
sponsors
science
191
IMPs

Activity Indicator

Last 6 months

9
Trials started
-25% vs previous period.
12
Trials started 6–12 months ago
103
Total trials linked
Highly Active
trending_downDeclining-25%
1
2
3
1
2
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 4 of 12 therapeutic areas and 15 of 191 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 188 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
61
Sponsors (total)
57
Active sponsors
45

Sponsor Network

Top 45 by active trials.

lock +44 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +22 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 566 other sites in Italy

description
Trial volume
103
Outperforms 90% of sites
public
Therapeutic diversity
13areas
Outperforms 87% of sites
groups
Sponsor diversity
57sponsors
Outperforms 89% of sites

Therapeutic Area Benchmark — Italy

Select a therapeutic area to compare against other sites in Italy.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Italy

Market Share

Country: Italy

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in San Camillo Forlanini Hospital

lock Showing 1 of 103 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Comparative Study of ABP 234 and Pembrolizumab in Patients with Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerAmgen Inc.Phase IRecruitingOct 2024

IMP list

lock Showing 1 of 191 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Cisplatin8Unknown2018-08-092025-11-18

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.